| Industry | 科学研究和技术服务业 | ||||||||||||||||||||||||
| Company Introduction | 公司是全球医药研发和制造领域创新化学产品和服务供应商，通过自身研发和生产平台为全球合作伙伴提供全方位的药物研究、开发和生产解决方案。公司所处行业为医药研发生产服务行业CXO（CRO、CDMO、CMO），该行业为创新药行业的研发和生产活动提供外包服务，其受创新药行业景气度影响较大，同时受到全球产业链转移趋势、地缘政治等多项因素影响。 2024年，面对复杂多变的外部环境，公司坚持以市场为导向，以客户为中心，持续提升交付能力与服务质量，推动技术平台创新与应用转化，积极应对全球生物医药投融资规模收缩、产业链需求端结构性调整、市场竞争激烈等不利因素。本报告期，公司营业收入16.89亿元，同比下降2.12%。第四季度，随着行业需求的初步改善及商业化项目订单交付，本季度营业收入5.61亿元，同比增长29.28%；叠加公司前期一系列降本控费、提质增效措施继续有效实施，2024年公司实现归属于上市公司股东的净利润2.20亿元，同比增长11.24%；扣除非经常性损益的净利润1.73亿元，同比下降1.66%。报告期内，公司加大客户信用管理与销售回款管理，优化资金使用，提升供应链效率管理水平，经营活动产生的现金流量净额3.03亿元，较2023年提升22.68%。公司聚焦客户需求，强化业务和市场拓展能力，年内客户访问及审计数量再创新高，2024年公司CDMO新签订单金额同比增长12.43%，订单数量增长31.12%。 | ||||||||||||||||||||||||
| Main Business | 药物分子砌块的设计、合成和销售；关键中间体的工艺开发、中试、商业化生产和销售；药物分子砌块的研发和工艺生产相关的技术服务。 | ||||||||||||||||||||||||
| Legal Representative | 杨民民 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 余善宝 | ||||||||||||||||||||||||
| Solicitors | 北京国枫律师事务所 | ||||||||||||||||||||||||
| Auditors | 中天运会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 025-86918230 | ||||||||||||||||||||||||
| Fax No | 025-86918262 | ||||||||||||||||||||||||
| Website | www.pharmablock.com | ||||||||||||||||||||||||
| ir@pharmablock.com;PB-Securities@PharmaBlock.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 10/11/2017 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 1.100 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.280 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 14.325 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 5.912B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Chiyu Banking Corporation Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |